
Yahoo Japan and Alphabet-backed Fractyl aims to make one of its proposed products a cornerstone therapy for type 2 diabetes, and has now raised about $270m in total.
Behavioural health platform developer Brightline captured $72m in a round led by GV, while Gopuff is set to buy Siemens and ST-backed mobility software producer RideOS.
The GlaxoSmithKline and Celgene-backed immunotherapy developer has floated in the middle of its range on the Nasdaq Global Market.
Alexandria Venture Investments was among the participants in a series A round for the cellular cancer therapeutics developer.
Limited partners including Alexandria Venture Investments and Royal Bank of Canada backed the healthcare technology-focused firm's first fund.
11Street and CJ Group contributed to a $71.8m round for on-demand logistics provider Barogo while Eli Lilly helped provide $66m for macrocycle drug developer Circle Pharma.
GV and Novo-backed cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.
SoftBank Vision Fund 2 co-led a series B round for immunotherapy developer Umoja Biopharma with Cormorant Asset Management.
The Johnson & Johnson, GSK and AstraZeneca-backed drug developer raised the cash in a Patient Square Capital-led round that took its total funding beyond $200m.
GV has participated in a $41.9m series B extension for the birth control delivery service, which increased the round's size to $92.9m.